Parmax Pharma Ltd Financial Ratios
PARMAXPHARMALTD · Healthcare · Current price
P/E ratio
—
P/B ratio
-4.9x
ROE
105.3%
ROCE
-12.4%
Debt / Equity
0.00
Dividend yield
0.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | — | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | -4.9x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 105.3% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | -12.4% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.00 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Parmax Pharma Ltd's latest numbers.
Parmax Pharma Ltd profitability
Parmax Pharma Ltd generates a return on equity of 105.3% and a return on capital employed of -12.4%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.00 and a P/E of —, Parmax Pharma Ltd is conservatively financed. Our overall business-quality score for the company is 4.0 / 10.
Understand the ratios
More on Parmax Pharma Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.